Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 1:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 234 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PROCRIT Clear all
Completed Phase 2 Interventional Results available

4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis

NCT01587898
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
46
States / cities
Azusa, California • Bakersfield, California • Chino, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 29, 2026, 1:45 AM EDT
Completed Phase 2 Interventional Results available

Darbepoetin Administration to Preterm Infants

NCT00334737
View directory record Official record
Conditions
Infant, Newborn
Interventions
Darbepoetin Alfa Injection, erythropoietin alfa injection, sham injection
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
1 Hour to 49 Hours
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
3
States / cities
Denver, Colorado • Ogden, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 29, 2026, 1:45 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy

NCT00267007
View directory record Official record
Conditions
Peripheral Neuropathy, Chemotherapy-induced
Interventions
PROCRIT 40,000 IU QW, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
28
States / cities
Mobile, Alabama • Little Rock, Arkansas • Alhambra, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Oct 29, 2026, 1:45 AM EDT
Completed Phase 3 Interventional

Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer

NCT00060398
View directory record Official record
Conditions
Anemia, Fatigue, Prostate Cancer
Interventions
epoetin alfa, dexamethasone
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
140
States / cities
Modesto, California • Aurora, Colorado • Boulder, Colorado + 92 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 29, 2026, 1:45 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Project CARE: CAncer Risk Evaluation

NCT07130487
View directory record Official record
Conditions
Primary Care
Interventions
Relational Agent ( RA) Alex
Behavioral
Lead sponsor
Anita Y. Kinney, PhD, RN
Other
Eligibility
18 Years to 70 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 29, 2026, 1:45 AM EDT
Terminated Phase 3 Interventional Results available

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

NCT00858364
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Anemia, Cancer, Lung Cancer
Interventions
Darbepoetin alfa, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
2,549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
277
States / cities
Anniston, Alabama • Birmingham, Alabama • Anchorage, Alaska + 243 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Oct 29, 2026, 1:45 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease

NCT02648347
View directory record Official record
Conditions
Anemia, Non-Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
208
States / cities
Huntsville, Alabama • Tuscumbia, Alabama • Glendale, Arizona + 148 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 29, 2026, 1:45 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve

NCT03682536
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Luspatercept, Epoetin alfa
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
25
States / cities
Berkeley, California • San Diego, California • Whittier, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 29, 2026, 1:45 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.

NCT00442416
View directory record Official record
Conditions
Anemia
Interventions
Epoetin alfa, methoxy polyethylene glycol-epoetin beta [Mircera]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Birmingham, Alabama • Bakersfield, California • Chula Vista, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Oct 29, 2026, 1:45 AM EDT
Completed Not applicable Interventional

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy

NCT00002073
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Epoetin alfa
Drug
Lead sponsor
Ortho Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Raritan, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 29, 2026, 1:45 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.

NCT00454246
View directory record Official record
Conditions
Anemia
Interventions
methoxy polyethylene glycol-epoetin beta, epoetin alfa, darbepoetin alfa
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
78
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2011 · Synced Oct 29, 2026, 1:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO)

NCT01913340
View directory record Official record
Conditions
Hypoxic-ischemic Encephalopathy, Neonatal Encephalopathy, Birth Asphyxia
Interventions
Erythropoietin, Normal saline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
30 Minutes to 24 Hours
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Little Rock, Arkansas • Palo Alto, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 29, 2026, 1:45 AM EDT
Completed Phase 4 Interventional

A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer

NCT00153868
View directory record Official record
Conditions
Anemia, Cancer
Interventions
darbepoetin alfa
Biological
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Oct 29, 2026, 1:45 AM EDT
Completed Phase 4 Interventional

Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation

NCT00425126
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Epoetin Alfa
Drug
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 27, 2010 · Synced Oct 29, 2026, 1:45 AM EDT
Completed Phase 3 Interventional

Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy

NCT00003341
View directory record Official record
Conditions
Anemia, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
epoetin alfa, quality-of-life assessment
Biological · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
18
States / cities
Berkeley, California • Los Angeles, California • Palm Springs, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Oct 29, 2026, 1:45 AM EDT
Completed Phase 3 Interventional Results available

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

NCT00338286
View directory record Official record
Conditions
Breast Cancer, Neoplasm Metastasis
Interventions
Standard supportive care (packed RBC transfusion), epoetin alfa + packed RBC transfusion
Other · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
2,098 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
14
States / cities
Anaheim, California • Gainesville, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Oct 29, 2026, 1:45 AM EDT
Not listed Phase 3 Interventional

An Open-label Trial to Determine Increased Red Blood Cell Production in Subjects With Anemia of Chronic Disease

NCT01846689
View directory record Official record
Conditions
Anemia of Chronic Disease
Interventions
ESS (medical food/drug)
Drug
Lead sponsor
Targeted Medical Pharma
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 29, 2026, 1:45 AM EDT
Completed Phase 2 Interventional Results available

Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy

NCT00416624
View directory record Official record
Conditions
Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
darbepoetin alfa, epoetin alfa, fatigue assessment and management, quality-of-life assessment
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 29, 2026, 1:45 AM EDT
Completed Not applicable Interventional

Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation

NCT00355407
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Darbepoetin alfa
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2009 · Synced Oct 29, 2026, 1:45 AM EDT
Terminated Phase 3 Interventional

Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy

NCT00083434
View directory record Official record
Conditions
Anemia, Cancer
Interventions
Epoetin alfa
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
6
States / cities
Anaheim, California • Arcadia, California • Fresno, California + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2011 · Synced Oct 29, 2026, 1:45 AM EDT
Completed Phase 2 Interventional Results available

A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.

NCT00364832
View directory record Official record
Conditions
Anemia
Interventions
methoxy polyethylene glycol-epoetin beta [Mircera]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
6
States / cities
Los Angeles, California • San Jose, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 29, 2026, 1:45 AM EDT
Completed Phase 2 Interventional

Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00077311
View directory record Official record
Conditions
Anemia, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Neutropenia
Interventions
darbepoetin alfa, pegfilgrastim, cisplatin, docetaxel, BNP7787
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
64
States / cities
Mountain View, California • Lewes, Delaware • Newark, Delaware + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Oct 29, 2026, 1:45 AM EDT
Recruiting Phase 3 Interventional

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

NCT07422480
View directory record Official record
Conditions
Myelodysplastic Syndrome, Anemia
Interventions
Elritercept, Epoetin Alfa
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
31
States / cities
Gilbert, Arizona • Duarte, California • Santa Rosa, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 29, 2026, 1:45 AM EDT
Withdrawn Phase 3 Interventional

Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

NCT03242967
View directory record Official record
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Northridge, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 29, 2026, 1:45 AM EDT